k.redgrave
TL2 Member · Aachen, DE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 6 June 2025 · last posted 14d · groups: regional-eu
96 posts, newest first. Showing up to 150.
-
A critique that turned out to be unfair, retracted by its author Replied, post #30 · Evidence › Study critique · 14 Jul 2026 · 14 likes I would be cautious about generalising from the critique example above. It is a good example. It is one example.
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #114 · Start Here › How to Ask · 10 Jul 2026 · 0 likes Asking a follow-up: new topic or reply in the old one? If the answer depends on the previous post, reply. If it is a question that makes sense without the previous…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #118 · Practice › Reconstitution · 10 Jul 2026 · 25 likes Helpful, and short, which on this subject is harder than long.
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #56 · Analytics › Impurities & related substances · 7 Jul 2026 · 19 likes Freeze-drying itself does not generate impurities in any significant way. Handling before and after it does, which is why transit conditions belong in the discussion. I…
-
Journal club: what we got wrong in an earlier session Replied, post #26 · Evidence › Journal club · 24 Jun 2026 · 10 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
-
Research-use-only status: what it means legally and practically Replied, post #59 · Compounds › Other compounds · 16 Jun 2026 · 4 likes Seconded. It reads as careful rather than confident, which is the right register.
-
CJC-1295 with and without DAC: what the modification does Replied, post #85 · Compounds › Secretagogues & GH axis · 16 Jun 2026 · 0 likes The claim about CJC-1295 upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
-
Transporting a vial for a weekend away — a second dataset Replied, post #79 · Practice › Storage & stability · 11 Jun 2026 · 7 likes This follows post #76 rather than contradicting it. Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or…
-
What steady state means for the decision to escalate Replied, post #11 · Practice › Dosing & titration · 9 Jun 2026 · 6 likes Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose.…
-
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Replied, post #30 · Compounds › Repair & healing peptides · 8 Jun 2026 · 0 likes Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted…
-
Tracking a shortage from primary sources rather than rumour Replied, post #41 · Access › Shortages · 8 Jun 2026 · 6 likes Agreed, and I will stop repeating the version of this I had been repeating.
-
MS/MS sequence confirmation: what it costs and when it is worth it — what changed since Replied, post #33 · Analytics › Mass spectrometry · 1 Jun 2026 · 16 likes That is consistent with mine, for whatever one more account is worth.
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 28 May 2026 · 0 likes Worth separating two things that the opening post runs together. Worth distinguishing the combination product from the two components bought separately and mixed. Those…
-
A site rotation scheme that is easy enough to actually follow Replied, post #63 · Practice › Administration · 14 May 2026 · 12 likes Confirming post #60 from a second method, which matters more than confirming it from a second person. A site rotation scheme that actually works: abdomen, outer thigh,…
-
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #59 · Practice › Storage & stability · 13 May 2026 · 33 likes Adsorption to container surfaces removes peptide from solution without changing how the solution looks. In dilute preparations that loss can be a meaningful proportion,…
-
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #3 · Devices › Syringes & needles · 8 May 2026 · 18 likes Answering the question the opening post raises rather than the one it answers. Filter needles are for drawing from glass ampoules where particulate is a real risk. For…
-
Revisiting: A field-by-field walk through a certificate of analysis Replied, post #31 · Analytics › COA interpretation · 3 May 2026 · 0 likes Reading rather than answering, but this is the post I would point somebody at.
-
[2026 update] Storing lyophilised material long term: what governs the shelf life Replied, post #105 · Practice › Storage & stability · 26 Apr 2026 · 5 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear.
-
Sample handling between despatch and injection Replied, post #68 · Analytics › Method validation · 25 Apr 2026 · 31 likes Picking up post #65: that is the part I would want checked first. Adding what did not work for me on sample handling between despatch, since the failures never get…
-
Sulfonylureas: the interaction most worth taking seriously Replied, post #5 · Practice › Interactions · 24 Apr 2026 · 6 likes Absence of an interaction study is not evidence of no interaction. A great many combinations discussed here have simply never been studied, and saying so is more useful…
-
[2026 update] Charge states for a 4 kDa peptide, worked through Replied, post #109 · Analytics › Mass spectrometry · 24 Apr 2026 · 0 likes Post #108 and I disagree about the size of the effect, not about the direction. Mass accuracy is expressed in parts per million. It is the difference between observed…
-
Anaesthesia and elective surgery: the aspiration question Replied, post #92 · Practice › Interactions · 19 Apr 2026 · 20 likes Adding thanks rather than a view. I do not have a view worth the space.
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #147 · Access › Pricing · 15 Apr 2026 · 11 likes Where a price includes consultation, device and follow-up, saying so makes a comparison possible. Most quoted figures do not.
-
Fasting versus non-fasting and which tests care Replied, post #6 · marked as the solution · Clinical › Bloodwork · 1 Apr 2026 · 8 likes An observation about fasting versus non-fasting that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than…
-
Coming back to: Why most self-reports here are not experiments, and that is fine Replied, post #57 · Research Methods › N-of-1 designs · 22 Mar 2026 · 18 likes Stopping rules: decide in advance when you will stop measuring (after a defined duration, after a defined number of measurements, or after a defined condition is met).…
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #97 · Lounge › Introductions · 17 Mar 2026 · 22 likes Following up: if you introduce yourself and someone asks a follow-up question, you can reply here or in a direct message depending on what feels right. I am aware this…
-
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #72 · Start Here › How to Ask · 10 Mar 2026 · 0 likes This settles it for me, at least until somebody posts a reason it should not.
-
Reading a regulatory notice rather than an article about it Replied, post #2 · Sourcing › Regulatory · 23 Feb 2026 · 0 likes Right — I had this wrong and I am glad to have read it before it mattered.
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #125 · Compounds › Semaglutide · 21 Feb 2026 · 0 likes Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the…
-
Micro-titration: a disputed topic, argued properly — one year on Replied, post #2 · Practice › Dosing & titration · 1 Feb 2026 · 7 likes The confident answers on Micro-titration and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
-
[2026 update] Confounding by indication, explained with a concrete example Replied, post #10 · Evidence › Study critique · 28 Jan 2026 · 0 likes A criticism that would apply equally to every trial in the field is worth stating once and is not a reason to discount a particular paper.
-
Revisiting: Language barriers in accessing a prescription abroad Replied, post #60 · Access › International · 17 Jan 2026 · 27 likes Right — I had this wrong and I am glad to have read it before it mattered.
-
Muscle cramps: the ordinary causes before the exotic ones Replied, post #43 · Practice › Side effects · 16 Jan 2026 · 10 likes Everything in post #39 holds. The case it does not cover is the one I have. I have been on both sides of the muscle cramps argument in this category within eighteen…
-
Why oral semaglutide needs an absorption enhancer at all Replied, post #59 · Compounds › Oral incretins · 17 Dec 2025 · 0 likes Thank you for taking the time. That was more work than a reply usually is.
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #91 · Compounds › Tirzepatide · 13 Dec 2025 · 5 likes The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement…
-
Journal club: LEADER as the historical anchor Replied, post #5 · Evidence › Journal club · 19 Nov 2025 · 4 likes The number people quote for LEADER is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on…
-
Waist circumference technique and its repeatability Replied, post #17 · Outcomes › Progress reports · 17 Nov 2025 · 0 likes The best progress reports here read as records rather than as arguments, and that difference is visible within a sentence. None of the above is medical advice and I am…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #30 · Clinical › Special populations · 12 Nov 2025 · 7 likes On older adults: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
-
Where the integrator drew the baseline, and how much it moved the number Replied, post #19 · Analytics › HPLC & UHPLC · 10 Nov 2025 · 20 likes That is clearer than the version I had in my head. Thank you.
-
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #4 · Data & Tools › Calculators · 9 Nov 2025 · 18 likes The opening post answers the question as asked. The question underneath it is different. Units: all calculators explicitly require units to be stated. This prevents the…
-
Where to report an adverse event officially, by region — a second dataset Replied, post #70 · Safety › Adverse events · 29 Oct 2025 · 2 likes Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.
-
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #137 · Compounds › Tirzepatide · 25 Oct 2025 · 27 likes Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you…
-
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #12 · Practice › Dosing & titration · 16 Oct 2025 · 3 likes Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose.…
-
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #102 · Evidence › Study critique · 15 Sep 2025 · 5 likes I changed my mind about Reverse causation after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the…
-
Payment method and the leverage it gives you, ranked Replied, post #14 · Sourcing › Payments · 15 Sep 2025 · 3 likes Refund policy before ordering: ask what the policy is if you receive damaged material or if the order is incorrect. Get it in writing or screenshot it. I would put the…
-
About the Site feedback category Replied, post #5 · Meta › Site feedback · 14 Sep 2025 · 1 like Feature request framed as feedback: the category list is long enough that a first-time reader cannot tell which four categories carry most of the traffic. A count next…
-
Aggregated purity results across four services, with caveats — a second dataset Replied, post #150 · Data & Tools › Datasets · 11 Sep 2025 · 4 likes I read post #148 twice before replying, because I had assumed the opposite. An honest declaration on Aggregated purity results across four: I have a prior here and it…
-
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #27 · Analytics › Method validation · 2 Sep 2025 · 26 likes Bookmarking this. I will come back when I have something worth adding.
-
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #20 · Wellbeing › Mental health · 28 Aug 2025 · 12 likes Answering the question post #16 raises rather than the one it answers. I have three months of notes on Anxiety and the honest summary is that the trend is real and the…
-
Distinguishing a deletion sequence by mass alone — the long version Replied, post #43 · Analytics › Mass spectrometry · 24 Aug 2025 · 17 likes Picking up post #42: that is the part I would want checked first. Mass accuracy is expressed in parts per million. It is the difference between observed and theoretical…
-
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Replied, post #3 · Compounds › Tirzepatide · 21 Aug 2025 · 0 likes Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not…
-
What a documentation review can and cannot tell you Replied, post #80 · Sourcing › Independent verification · 19 Aug 2025 · 7 likes For anyone finding this later: the short answer on documentation review is that it depends on one thing, and the rest of the thread is people identifying which thing.
-
Which panel is worth repeating and which is worth ignoring Replied, post #86 · Clinical › Bloodwork · 16 Aug 2025 · 0 likes A trend needs at least three points to be a trend. Two points are a line and a line through noise is still a line. A modest claim, modestly supported.
-
A request that was declined, and the reasoning — a second dataset Replied, post #57 · Documentation › Wiki requests · 11 Aug 2025 · 11 likes Bookmarking this. I will come back when I have something worth adding.
-
Coming back to: When "no data" is the complete and final answer Replied, post #79 · Compounds › Other compounds · 10 Aug 2025 · 0 likes Narrowing post #76, because the general version has more than one answer. Anyone submitting an unusual compound for testing should tell the laboratory what it is rather…
-
Follow-up: Why appetite effects are mostly central Replied, post #13 · Pharmacology › Receptor biology · 7 Aug 2025 · 15 likes Something worth flagging about appetite effects: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a…
-
A request that was declined, and the reasoning — a second dataset Replied, post #17 · Documentation › Wiki requests · 6 Aug 2025 · 10 likes Post #14 answers the question as asked. The question underneath it is different. Requests for a page summarising a supplier are declined, because that is what the…
-
Antibiotics and a course of something with delayed emptying Replied, post #99 · Practice › Interactions · 24 Jul 2025 · 4 likes Adding the measurement that post #96 says would settle it. Food interactions: most interactions are absorption interactions. Some medications absorb better with food,…
-
About the Datasets category Replied, post #11 · Data & Tools › Datasets · 18 Jul 2025 · 22 likes Thank you for taking the time. That was more work than a reply usually is.
-
A field-by-field walk through a certificate of analysis Replied, post #101 · Analytics › COA interpretation · 17 Jul 2025 · 1 like I read post #97 twice before replying, because I had assumed the opposite. Field-by-field walk through a certificate looks different depending on whether you are…
-
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #30 · Practice › Reconstitution · 10 Jul 2025 · 0 likes Narrowing post #29, because the general version has more than one answer. Research-use-only material reconstituted at home is not a compounded sterile preparation and…
-
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #66 · Evidence › Trials · 1 Jul 2025 · 18 likes Number needed to treat is only interpretable with the duration attached. The same NNT over one year and over five years describes very different clinical situations.
-
Forced degradation studies: designing one that is informative — does this still hold? Replied, post #26 · Analytics › Method validation · 29 Jun 2025 · 0 likes Specificity is the first question: does the method separate the analyte from everything reasonably expected to be present? A method that has not been challenged with…
-
[2026 update] An appeal that failed, and what I would do differently Replied, post #109 · Access › Insurance & coverage · 14 Jun 2025 · 2 likes Answering the question post #105 raises rather than the one it answers. Offering a way to settle appeal rather than another opinion about it. Two measurements, taken…
-
Validating a calculator against hand arithmetic — what changed since Replied, post #98 · Data & Tools › Calculators · 29 May 2025 · 32 likes The most useful reply I ever got about Validating a calculator against hand was a request to state my units. It sounds like pedantry and it has saved me twice.
-
Travel coolers and how long they really hold — the long version Started this topic · Devices › Cold chain · 17 May 2025 · 23 likes Travel coolers and how long they really hold — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about Travel…
-
Coverage for the indication versus for the drug Replied, post #65 · Access › Insurance & coverage · 14 May 2025 · 8 likes Coming back to post #63, because the follow-up matters more than the original answer. Reimbursement changes: a compound covered one year might not be the next. A…
-
Payment mechanics and the recovery options that do not exist — what changed since Replied, post #7 · Sourcing › Payments · 2 May 2025 · 12 likes Building on post #6 rather than restating it. Reading back through the Payment mechanics threads from last year, the same three questions come up every time and only…
-
Titles that describe the question, not the situation Replied, post #4 · Start Here › How to Ask · 30 Apr 2025 · 0 likes Thank you for the correction. I would rather find out here than later.
-
A report I filed that turned out to be wrong, and the correction Replied, post #21 · Sourcing › Vendor reports · 20 Apr 2025 · 26 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
-
Vagal afferents and the gut-brain pathway Started this topic · Pharmacology › Receptor biology · 7 Apr 2025 · 36 likes On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not…
-
Adjudicated events and why the definition matters — the long version Replied, post #79 · Evidence › Trials · 3 Apr 2025 · 31 likes That is clearer than the version I had in my head. Thank you.
-
Pharmaceutical compounding rules, summarised from primary sources Replied, post #144 · Sourcing › Regulatory · 5 Mar 2025 · 5 likes Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #21 · Evidence › Meta-analyses · 29 Jan 2025 · 0 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Second pass at: Certificates issued by the seller versus by a laboratory Replied, post #65 · Analytics › COA interpretation · 27 Jan 2025 · 0 likes An itemised related-substances table with retention times says considerably more about the synthesis than a single total. A total tells you how much is not the main…
-
Why we hide unevidenced fraud accusations and log the hiding Replied, post #43 · Sourcing › Red flags · 24 Jan 2025 · 13 likes The strongest single signal available cheaply is what happens when you ask a technical question. A quantitative answer inside a working day is difficult to fake at scale.
-
Biased agonism: a real phenomenon, an over-used explanation — what changed since Replied, post #23 · Pharmacology › Receptor biology · 11 Jan 2025 · 17 likes Filing a mild objection to the consensus on Biased agonism. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
-
Follow-up: Individual participant data versus aggregate data Replied, post #12 · Evidence › Meta-analyses · 8 Jan 2025 · 0 likes Coming back to post #10, because the follow-up matters more than the original answer. The documentation on Individual participant data versus aggregate is better than…
-
UK access routes, dated and sourced — a second dataset Replied, post #22 · Regional › UK & Ireland · 1 Jan 2025 · 19 likes Answering the question post #20 raises rather than the one it answers. The most useful contribution is a link to the current official page with the date you accessed…
-
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #10 · Compounds › Semaglutide · 28 Dec 2024 · 24 likes Everything in post #8 holds. The case it does not cover is the one I have. On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with…
-
Oxidation pathways for methionine and tryptophan Replied, post #10 · Analytics › Impurities & related substances · 26 Dec 2024 · 0 likes The documentation on oxidation pathways for methionine is better than this thread and I say that as someone who has posted in the thread.
-
Coming back to: Oxidation pathways for methionine and tryptophan Replied, post #3 · Analytics › Impurities & related substances · 18 Dec 2024 · 5 likes Distinguishing three things in the Oxidation pathways for methionine discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the…
-
Washout with a one-week half-life: the arithmetic Replied, post #34 · Research Methods › N-of-1 designs · 29 Nov 2024 · 20 likes An n of one tells you about one person, which is the person you are most interested in. That is the whole value and it is not nothing.
-
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #41 · Sourcing › Regulatory · 28 Nov 2024 · 0 likes The most useful thing anyone has posted about Research-use-only labelling in this category was a table of what had been measured and by whom. That is what I would want…
-
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #42 · Clinical › Special populations · 23 Nov 2024 · 1 like Athletes and people in substantial training loads are effectively unstudied, and the questions asked here about performance have no trial evidence behind them at all.…
-
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #2 · Clinical › Special populations · 18 Nov 2024 · 3 likes The opening post answers the question as asked. The question underneath it is different. I read the earlier replies on Type 1 diabetes twice before writing this,…
-
Buffers, pH and why a formulation is a formulation Replied, post #13 · Pharmacology › Formulation chemistry · 30 Oct 2024 · 25 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #3 · Compounds › Semaglutide · 28 Oct 2024 · 0 likes The opening post answers the question as asked. The question underneath it is different. Approved indications differ by jurisdiction and change. As of mid-2026 the…
-
Irish differences from the UK position Replied, post #58 · Regional › UK & Ireland · 25 Oct 2024 · 0 likes Sensible. I would want the same detail before I acted on it either.
-
Why I ask for the gradient before I discuss the number Replied, post #24 · Analytics › HPLC & UHPLC · 30 Sep 2024 · 26 likes Adding the measurement that post #23 says would settle it. Injection volume matters because column overload distorts peak shape, and an overloaded main peak can swallow…
-
Telehealth prescribing models in the US Replied, post #3 · Regional › North America · 7 Sep 2024 · 2 likes Coming back to the opening post, because the follow-up matters more than the original answer. On telehealth prescribing models the community has more anecdote than the…
-
Reporting a discrepancy without making an allegation Replied, post #18 · Sourcing › Vendor reports · 7 Aug 2024 · 29 likes The cost of a submission is worth stating. It is the main reason people do not do this and knowing the figure helps somebody else decide.
-
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated… Replied, post #3 · Compounds › Secretagogues & GH axis · 4 Aug 2024 · 0 likes CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do…
-
Guidelines revision: what changed and why Replied, post #120 · Meta › Announcements · 28 Jul 2024 · 22 likes Appreciated. The plain phrasing does more work here than a longer post would.
-
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #119 · Practice › Dosing & titration · 10 Jul 2024 · 28 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
-
Two sessions a week versus four: what the evidence supports — a second dataset Replied, post #14 · Nutrition & Training › Resistance training · 20 Jun 2024 · 3 likes Recording sessions is what makes progression visible. Without a log, load creep and load decline both go unnoticed.